atDose was founded on September 1, 2017 in Yokohama City, Kanagawa, Japan. We are developing a mobile-type dosing and infusion device that can dispense ultra-small doses at precise target points. The lightweight portable intravenous device can be used to support the treatment of diseases such as brain tumors, retinal disease, and breast cancer. With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases. For example, side effects such as stomatitis, hair loss, and nausea with anticancer drugs are one of eternal difficulty of medicine. Our ultra-micro-dosing device enables localized, targeted and continuous dosing. Thus, side effects should be reduced while maintaining the efficacy of the drug. Since an animal study has proved our device efficacy, we can go through clinical trial of any cancer therapy. Furthermore, any drug combination can be freely applied with newly approvable dosing amount, therefore, our device will be a novel drug delivery system as a platform technology. We also aim to improve patients' Quality of Life (QoL) with increasing the option of medication procedure. In addition to the conventional treatment, our platform technology will provide an additional procedure that respects patients' preference of QoL . We strongly believe this will improve present medication.
Using a combination of micro needles and an electro-osmotic pump, such as those used in acupuncture, the drug is administered directly to the affected area to reduce the physical burden of side effects of medication, especially in cancer patients. We hope that this product will provide a new means of administering medication and contribute to unmet medical needs. Our core technology, the electro-osmotic flow pump, makes the drip infusion device compact and portable by enabling ultra low volume dosing over a long period of time. We offer a compact, light, inexpensive and easy to adjust infusion pump that replaces the large, heavy and expensive pumps of the past. The pump can be remotely operated via a smartphone or tablet device in combination with IoT technology to mix multiple drugs, continuously switch dosing and adjust drug doses based on patient vital data. The aim is to develop an infusion pump that is easy to handle even in limited space, such as for neonates who want to receive extremely low doses of medication, and for mobile situations such as emergency treatment and home treatment. It will relieve the patient from burden of conventional suspended drip device and bed restraints, making it easier to move around and thus contributing to improving the patient’s quality of life. In combination with IoT technology, the device can be operated remotely to reduce the burden of family members and nurses in monitoring the patient.
Voice from Acceralator
Medical device, Pre-Clinical, 2017 atDose is a medical device startup creating a mobile-type dosing and infusion device that can dispense ultra-small doses directly into the affected area with an electro-osmotic pump. The lightweight portable intravenous device is used to support the treatment of diseases such as brain tumors, retinal disease, and breast cancer. Compared to existing oral medications, their device can reduce the serious side effects with precise dose control. With this device, they aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases including new uses of existing drugs as well as developing drugs.